Methods and Compositions for Modulating Angiogenesis
First Claim
1. A composition comprising an antisense nucleic acid comprising a nucleotide sequence that is complementary to a nucleotide sequence included in a miR-126 nucleic acid, wherein the antisense nucleic acid comprises a nucleotide sequence capable of forming a stable duplex with a portion of the miR-126 nucleic acid comprising a ribonuclease III cleavage site, and wherein the antisense nucleic acid has a length of from about 20 nucleotides to about 50 nucleotides.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides compositions comprising antisense nucleic acids that reduce miR-126 levels in an endothelial cell. The present invention provides compositions comprising a target protector nucleic acid. The present invention provides methods of modulating angiogenesis in an individual, the methods generally involving administering to the individual an effective amount of an agent that increases or that decreases the level of miR-126 in endothelial cells of the individual.
-
Citations
59 Claims
- 1. A composition comprising an antisense nucleic acid comprising a nucleotide sequence that is complementary to a nucleotide sequence included in a miR-126 nucleic acid, wherein the antisense nucleic acid comprises a nucleotide sequence capable of forming a stable duplex with a portion of the miR-126 nucleic acid comprising a ribonuclease III cleavage site, and wherein the antisense nucleic acid has a length of from about 20 nucleotides to about 50 nucleotides.
-
5. (canceled)
-
7-17. -17. (canceled)
- 18. A method of reducing angiogenesis in a mammal, the method comprising administering to a mammal in need thereof an effective amount of an agent that decreases a level and/or activity of miR-126 in an endothelial cell in the mammal.
-
21. (canceled)
-
24-26. -26. (canceled)
-
29-32. -32. (canceled)
- 33. A method of increasing angiogenesis in an individual, the method comprising administering to a mammal having a disorder that is treatable by increasing angiogenesis an effective amount of an agent that increases a level of miR-126 in an endothelial cell in the mammal, wherein said agent is a recombinant nucleic acid comprising a nucleotide sequence encoding a miR-126 nucleic acid.
-
34. (canceled)
-
36. (canceled)
-
39-42. -42. (canceled)
- 43. A synthetic target protector nucleic acid that binds to a miR-126 target mRNA, wherein the target protector nucleic acid does not induce cleavage or translational repression of the target mRNA, and wherein the target protector nucleic acid inhibits binding of a miR-126 to the miR-126 target mRNA.
-
47. (canceled)
-
49-53. -53. (canceled)
-
55. (canceled)
- 56. A synthetic competitive inhibitor nucleic acid comprising a nucleotide sequence that is complementary to a mature miR-126 nucleic acid and that inhibits binding of a mature miR-126 to a miR-126 target.
Specification